Background. Accurate quantification of the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance in patients who are receiving antiretroviral therapy (ART) is difficult, and results from previous studies vary. We attempted to assess the prevalence and dynamics of resistance in a highly representative patient cohort from Switzerland.
Methods. On the basis of genotypic resistance test results and clinical data, we grouped patients according to their risk of harboring resistant viruses. Estimates of resistance prevalence were calculated on the basis of either the proportion of individuals with a virologic failure or confirmed drug resistance (lower estimate) or the frequencyweighted average of risk group-specific probabilities for the presence of drug resistance mutations (upper estimate).
Results. Lower and upper estimates of drug resistance prevalence in 8064 ART-exposed patients were 50% and 57% in 1999 and 37% and 45% in 2007, respectively. This decrease was driven by 2 mechanisms: loss to follow-up or death of high-risk patients exposed to mono-or dual-nucleoside reverse-transcriptase inhibitor therapy (lower estimates range from 72% to 75%) and continued enrollment of low-risk patients who were taking combination ART containing boosted protease inhibitors or nonnucleoside reverse-transcriptase inhibitors as firstline therapy (lower estimates range from 7% to 12%). A subset of 4184 participants (52%) had у1 study visit per year during [2002] [2003] [2004] [2005] [2006] [2007] . In this subset, lower and upper estimates increased from 45% to 49% and from 52% to 55%, respectively. Yearly increases in prevalence were becoming smaller in later years.
Conclusions. Contrary to earlier predictions, in situations of free access to drugs, close monitoring, and rapid introduction of new potent therapies, the emergence of drug-resistant viruses can be minimized at the population level. Moreover, this study demonstrates the necessity of interpreting time trends in the context of evolving cohort populations.
During the past decade, combination antiretroviral therapy (cART) has markedly decreased morbidity and of drug resistance against cART will inevitably worsen with prolonged duration of antiretroviral therapy (ART) and eventually leave many HIV-1-infected patients without treatment options [11, 12] . Our overall aim was to reexamine those predictions in light of the recent advances in HIV medicine, such as the registration of new antiretroviral compounds. We assessed drug resistance prevalence over time in ART-experienced patients of the Swiss HIV Cohort Study with genotypic information available. Moreover, we sought to extend those estimates to the study population without available drug resistance tests by estimating their risk for the presence of drug resistance mutations on the basis of treatment history and measurements of HIV RNA concentration.
METHODS
Study population. The Swiss HIV Cohort Study is a nationwide cohort study with continuous enrollment and semiannual study visits [2] . The Swiss HIV Cohort Study has been approved by the ethics committees of all participating institutions, and written informed consent is obtained from participants. The Swiss HIV Cohort Study drug resistance database contains the results of all genotypic tests performed by the 4 laboratories engaged in resistance testing in Switzerland stored in a central database (SmartGene; Integrated Database Network System version 3.5.0) [13] . Drug resistance was defined as the presence of у1 major mutation of the fall 2007 International AIDS Society-USA drug mutation list [14] . Mutations that confer resistance to fusion inhibitors were not considered. In addition, the following mutations listed as specific for etravirine were excluded, because several of them may be polymorphic, and inclusion of them would yield exaggerated prevalence estimates (A. U. Scherrer, V.v.W., H.F.G.; unpublished data): V90I, A98G, K101E/H/P, V106I, E138A, V179D/F/T, Y181V, and M230L.
This study included ART-experienced patients who attended at least 1 visit after 1 January 1999. For patients who initiated ART before enrollment in the Swiss HIV Cohort Study, inclusion was restricted to individuals with a sufficiently documented treatment history to assess their probability for the presence of drug resistance mutations. In particular, for each therapy started before Swiss HIV Cohort Study enrollment, у1 ontreatment HIV RNA measurement at least 180 days after therapy start was required for inclusion. To assess the impact of continuous enrollments and dropouts of participants on prevalence estimates, we repeated all analyses on a subset of individuals who had been seen in each year between 2002 (1 year after the introduction of lopinavir in Switzerland) and 2007. This subgroup was termed the "closed cohort," in contrast to the "open cohort," which included all patients seen since 1999.
Statistical analysis. To estimate the prevalence of drug resistance, we classified all cohort patients into 2 prespecified categories. The first group consisted of patients considered at high risk for the emergence of drug-resistant HIV, either because they had experienced virologic failure while receiving therapy or because they had been exposed to single or dual nucleoside reverse-transcriptase inhibitor (NRTI) therapy (virologic failure group). We defined virologic failure as 2 consecutive plasma HIV RNA levels 1500 copies/mL after 1180 days of ART or a single HIV RNA level 1500 copies/mL followed by discontinuation or modification of treatment. The second group included individuals who were at low risk for the emergence of resistance because they were either not undergoing treatment or had remained virologically suppressed while receiving therapy, defined as at least 2 consecutive viral loads of !50 copies/mL while receiving the same treatment in a given year (low-risk group), whereby undetectable HIV RNA levels were coded as the detection limit minus 1 copy. All remaining patients were classified as having an unknown status (the unknown group). For an estimate of prevalence of resistance within these groups, genotypic tests were classified according to the patients' group memberships at time of sampling, and the proportion of tests with at least 1 major International AIDS Society-USA resistance mutation was calculated for each group. Tests from the low-risk and unknown groups were performed while the patients were not undergoing treatment, during the initial viral load decay while undergoing treatment, or during intermittent viremia (viral load, р500 copies/mL) while receiving therapy. It was assumed that, once detected, transmitted or acquired mutations would persist.
We derived lower-bound and upper-bound estimates of drug resistance prevalence. The upper bound was defined as the mean of group-specific probabilities of the presence of drug resistance mutations for the virologic failure, low-risk, and unknown groups, weighted by the respective group size. This approach assumed that patients with a genotypic test from the low-risk and unknown groups (i.e., those without indication for testing according to guidelines [15] ) were representative of the remaining individuals from their respective groups. The lower bound estimate was calculated as the proportion of patients either belonging to the virologic failure group or who were members of the low-risk and unknown groups with test results positive for drug-resistant HIV. Linear time trends in prevalence estimates were assessed using a generalized linear model [16] . Trend analyses were stratified according to the first ART received: patients who had started with standard cART containing at least 3 drugs from 2 classes [17] and those who had initially received treatments not qualifying as cART, which were subsumed under the historic ART group. Most (89%) of these latter patients were treated with 1 or 2 NRTIs as first therapy; 4% had received 3 NRTIs that contained abacavir. The remaining patients had received non-NRTIs (NNRTIs) or protease inhibitors (PIs) combined with 1 NRTI. The cART group was further divided to account for the differences in potency between unboosted PIs (cART group) and newer treatments, including either an NNRTI or a ritonavir-boosted PI (potent cART group) [13, 18] . Sensitivity analyses were conducted by restricting estimation of prevalence to genotypic tests performed on treatment and by considering patients lost to follow-up as having experienced virologic failure. Conclusions were not altered by these analyses. (table 1) . Figure 1A summarizes the evolution of the open cohort. The size of the ART-experienced population increased, whereas the population of patients with exposure to mono-or dual-NRTI treatment or with virologic failures diminished over time. The proportion of patients who had undergone genotypic resistance testing after initiation of ART also increased steadily, although the slowed growth from 2004 onward suggests that, in recent years, the numbers of patients with an indication for testing and tests performed have reached a steady state: fewer patients experienced virologic failure, and those who had experienced virologic failure were more likely to have undergone resistance testing. In fact, among patients who experienced virologic failure while receiving ART, 80% had undergone at least 1 genotypic resistance test by 2007, up from 41% in 1999 (data not shown).
RESULTS

Patient
Estimation of drug resistance prevalence. To determine the prevalence of resistance, we classified ART-exposed patients by their probability of harboring resistant viruses based on their treatment history. (95% CI, 29.6%-40.3%; number of tests, 322) for patients in the unknown group. In the open cohort, the lower estimate of resistance prevalence for 2007, under the assumption that probabilities for resistance mutations in the low-risk and unknown groups were 0 unless confirmed by resistance testing (figure 2A), was 37.4%.
For the upper estimate, resistance prevalence derived from tested patients in the low-risk and unknown groups was extrapolated to all untested individuals in these groups and yielded a prevalence of 45.1% for 2007. Those numbers were notably lower than estimates obtained for 1999 (49.7% [lower] and 56.6% [upper] ). In the closed cohort, lower and upper d Age and year of ART initiation were included as confounders and modeled as cubic splines with knots at the 25th, 50th, and 75th centiles. e The CD4 cell count at ART initiation was included as a confounder and modeled as a categorical variable with 4 groups on the basis of centiles and an additional category for missing data.
estimates were continuously increasing from 45.0% to 49.4% (lower) and from 51.7% to 54.6% (upper) from 2002 through 2007 (figure 2B); this was to be expected, however, because of our approach to carry forward detected resistance mutations. Different trends also emerged when analyses were repeated with stratifications for type of initial ART ( figure 3 ). With the exception of the historic ART group, in whom resistance mutations are already frequent, prevalence of resistance generally appeared to be increasing over time. Change rates derived from lower estimates were 1.5 (open cohort) and 1.2 (closed cohort)
percentage points per year for the cART group and 0.6 (open) and 1.6 (closed) percentage points for the potent cART group, respectively (figure 3B). However, increases, especially those for lower estimates, tended to be much steeper during the first few years of our observational period ( figure 3A) , and thus, linear trends must be interpreted cautiously. Shifts in study population as explanation for time trends. To explore reasons for the differences in time trends between the open and closed cohorts, we analyzed shifts in the distribution of patients exposed to different first-line treatments (historic ART group, cART group, and potent cART group), symbolic for different propensities for the presence of drug-resistant HIV. According to figure 4A , the number of patients who had initiated therapy with potent combinations increased steadily (2441 patients [39.1%]) and exceeded the number of patients from the historic ART category (2181 patients [35.0%]) by 2007. Figure 4B indicates a decrease in the number of patients with virologic failure or exposure to mono-or dual-NRTI therapy and who are, thus, at high risk for the emergence of drug resistance mutations. This decrease was caused by a continuous loss of patients exposed to historic ART as initial treatment from the study population, which was confirmed with a multinomial logistic regression model to study factors associated with losses to follow-up or deaths (table 2) . Of further note, the availability of a genotypic drug resistance test was associated with a smaller probability for being lost to follow-up or death, most likely because this may also be an indicator for good patient compliance and regular attendance of physician appointments. After controlling for resistance testing, the presence of International AIDS Society-USA drug resistance mutations was not associated with a higher probability of death, although crude percentages would suggest so.
DISCUSSION
On the basis of data from a highly representative cohort for the HIV-1 epidemic in Switzerland, we estimate that drug resistance prevalence in ART-exposed patients decreased from 1999 through 2007 in the population of HIV-infected patients. Our upper estimate was 57% in 1999 and 45% in 2007, whereas our low estimate was 50% in 1999 and 37% in 2007. Such apparent time trends must be interpreted cautiously and in the context of the changing composition of the HIV-1-infected population over time. The proportion of patients exposed to historic ART, such as single-class NRTI therapy, generally regarded as a population with a high prevalence of drug-resistance mutations, decreased markedly. On the other hand, the patient group treated with combination therapy from the start and therefore at a much lower risk for the emergence of drug resistance grew over time, thus leading to a dilution effect. In contrast, when analyzing trends within a fixed subset of patients, drug resistance prevalence was increasing steadily as expected, yet at progressively smaller rates. Thus, our analysis demonstrates the potential biases and pitfalls of time trends derived from cohorts with continuous enrollment, if shifts in population composition are not considered.
Compared with other surveys, estimates of drug resistance prevalence from this study were considerably lower and most likely reflect the different methods. Most studies relied on analyses of drug resistance databases, which yielded probabilities for the presence of at least 1 drug resistance mutation of 76%-90% [19] [20] [21] [22] [23] [24] . However, patients who had undergone drug resistance tests are not representative of the entire ART-exposed population, and studies of such patients tend to be biased toward patients who had experienced problems while undergoing therapy. For example, in the Swiss HIV Cohort Study in 2007, 44% of ART-exposed patients had never experienced a virologic failure and thus had no indication for drug resistance testing.
Results from the present study are in line with a survey from the United States that relied on cross-sectional sampling, which estimated the prevalence of resistance mutations at 76% among viremic patients with an HIV RNA level 1500 copies/mL [25] . Since viremic patients represented ∼63% of the HIV-1-infected population, this yields an estimate of 48% for ART-exposed patients in the United States in 1998.
At the lower end of published estimates are the results from Pillay et al. [21] , who obtained a prevalence in the United Kingdom of 17% in 2002 by dividing the number of patients who had ever had a positive drug resistance test result by the estimated number of treated patients in that year. Our approach extends their analysis by further including clinical and virologic information in the estimates, permitting an estimate of drug resistance prevalence in the population without resistance tests available.
Results from the analysis enclosing all participants seen since 1999 indicated an overall decrease of levels of drug resistance in the Swiss HIV Cohort Study, at first glance contradicting earlier predictions from mathematical models [12] . Yet those apparent trends were most likely caused by the turnover of high-and low-risk populations in the Swiss HIV Cohort Study. When reanalyzed within a fixed sample of patients (our closed cohort) or within groups of initial treatment, prevalence was increasing over time as predicted by the models. Those yearly increases were remarkably low, however. In their study from 2001, Blower et al. [11] considered a yearly rate of resistance emergence of 10%-an optimistic scenario. With use of virologic failure as a proxy for resistance emergence, we estimated rates of 4.7% (95% CI, 4.4%-5.1%) per 100 person-years of receiving ART for patients who had initiated treatment with cART and 2.1% (95% CI, 1.8%-2.4%) for those who had started with potent cART ( , by log rank test) [13] . These P ! .001 lower rates most likely reflect the high standard of general health care in Switzerland and the introduction of boosted PIs.
Which of the estimation approaches presented herein may be the most realistic? We believe that lower estimates from the open cohort most closely resemble the situation of the HIVinfected population in Switzerland and are thus most relevant, because in patients without virologic failure or exposure to mono-or dual-NRTI treatment, the upper estimate approach makes a strong assumption of representativeness of individuals with confirmed genotypic resistance. Of the 4295 study participants who had never experienced virologic failure (i.e., the low-risk and unknown groups), 306 patients (7.1%) had test results that indicated the presence of resistance mutations. Of these 306 patients, 181 (59.2%) had also undergone a resistance test at baseline, and primary resistance mutations were detected in 142 (78.5%) of these 181 tests. Thus, upper estimates were disproportionately affected by primary drug resistance because prevalence of transmitted resistance is estimated to be 10% for Switzerland [26] .
In turn, the lower method tended to underestimate prevalence, because pretreatment resistance testing has not been performed uniformly in individuals from the low-risk and unknown groups, although 64.5% of them had undergone at least 1 genotypic resistance test by 2007. Thus, assuming a primary resistance prevalence of 10% for these 35.5% untested patients yielded a new lower estimate of 40.7% for 2007, compared with 37.4% from the initial analysis, which suggests that the impact of testing bias on lower estimates was minimal in our sample.
The Swiss HIV Cohort Study is highly representative of the epidemic in Switzerland because it encompasses 49% of all diagnosed HIV-infected individuals (http://www.shcs.ch). Moreover, the Swiss HIV Cohort Study drug resistance database contains all genotypic resistance tests performed in Switzerland, making this one of the most comprehensive data sets on resistance worldwide. An assessment of completeness of this database revealed no systematic biases with regard to mode of HIV acquisition or ethnicity (V.v.W., B.L., H.F.G.; unpublished data). Thus, the open cohort approach should closely mirror the dynamics not only in Switzerland but also in other countries with a highly developed health care system. A potential limitation for interpretation is the loss to follow-up rate, which totalled 16% by the end of 2007. These patients were more likely to have acquired HIV infection by injection drug use or to originate from countries outside northwestern Europe (i.e., immigrants and asylum seekers)-populations that are known to be harder to reach and that tend to have a higher attrition from studies. In comparison to the closed cohort assessment, prevalence estimates from the open cohort were ∼12% lower in 2007, thus suggesting an impact of losses to follow-up on our estimates. Most likely, the true bias is smaller than 12%, because the population included in the closed cohort tended to have a worse risk profile for virologic failures and, thus, emergence of resistance in terms of treatment history and the higher proportion of injection drug users (table 1) .
To summarize, we conclude from our findings that HIV drug resistance, although still a significant problem in highly treated populations, appears to be moderating over time in highly developed health care systems with adequate resources. We speculate that resistance prevalence will further decrease at the population level because of the observed dilution effects, but also, and more importantly, because durable therapy success can more often be achieved with newer drugs and thus the emergence of new drug resistance is considerably slowed. The situation in developing countries, where state-of-the-art diagnostic tools often are not routinely available and therapeutic options are still limited, is likely to be different. In such settings, the possibility of increasing drug resistance requires close monitoring.
